{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:58:41Z","timestamp":1790834321904,"version":"4.1.0"},"reference-count":32,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,30]]},"DOI":"10.18632\/oncotarget.11019","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T02:10:09Z","timestamp":1470190209000},"page":"56219-56232","source":"Crossref","is-referenced-by-count":113,"title":["Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies"],"prefix":"10.18632","volume":"7","author":[{"given":"Kevin H.","family":"Chen","sequence":"first","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Wada","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia E.","family":"Firor","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Pinz","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jares","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Salman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Golightly","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshuo","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Jiang","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupo","family":"Ma","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY, USA"},{"name":"Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA"},{"name":"Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Tobinai","year":"2011","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"June","year":"2014","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/PPO.0000000000000031","article-title":"CD19-CAR trials","volume":"20","author":"Dotti","year":"2014","journal-title":"Cancer journal"},{"key":"4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Ma","year":"2016","journal-title":"Leukemia"},{"key":"5","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Pileri","year":"2010","journal-title":"Pathologica"},{"key":"6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.bmt.1704317","article-title":"Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells","volume":"33","author":"June","year":"2004","journal-title":"Bone marrow transplantation"},{"key":"7","first-page":"21","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Koehl","year":"2015","journal-title":"Frontiers in pharmacology"},{"key":"8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Dotti","year":"2010","journal-title":"Leukemia"},{"key":"9","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1535370215584936","article-title":"From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy","volume":"240","author":"Ma","year":"2015","journal-title":"Experimental biology and medicine"},{"key":"10","doi-asserted-by":"crossref","first-page":"14053","DOI":"10.1038\/mtm.2014.53","article-title":"Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies","volume":"1","author":"Dunbar","year":"2014","journal-title":"Molecular therapy Methods & clinical development"},{"key":"11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Tonn","year":"2016","journal-title":"Cancer immunology, immunotherapy"},{"key":"12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Kuhlcke","year":"2015","journal-title":"Molecular therapy"},{"key":"13","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Bug","year":"2013","journal-title":"Cytotherapy"},{"key":"14","first-page":"108","article-title":"ErbB2\/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma","author":"Wels","year":"2016","journal-title":"Journal of the National Cancer Institute"},{"key":"15","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","article-title":"Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells","volume":"33","author":"Klingemann","year":"2009","journal-title":"Leukemia research"},{"key":"16","doi-asserted-by":"crossref","first-page":"e26527","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Klingemann","year":"2013","journal-title":"Oncoimmunology"},{"key":"17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance inandantitumor activity against human multiple myeloma","volume":"28","author":"Yu","year":"2014","journal-title":"Leukemia"},{"key":"18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Hou","year":"2014","journal-title":"Molecular oncology"},{"key":"19","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","article-title":"Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells","volume":"20","author":"Brenner","year":"2006","journal-title":"Leukemia"},{"key":"20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Campana","year":"2004","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/j.1875-9114.1991.tb03595.x","article-title":"Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation","volume":"11","author":"Millikan","year":"1991","journal-title":"Pharmacotherapy"},{"key":"22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/138945009787354539","article-title":"Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma","volume":"10","author":"Woo","year":"2009","journal-title":"Current drug targets"},{"key":"23","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1053\/j.gastro.2007.08.035","article-title":"A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis","volume":"133","author":"Lowder","year":"2007","journal-title":"Gastroenterology"},{"key":"24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1177\/0091270009356299","article-title":"Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes","volume":"50","author":"Waldmann","year":"2010","journal-title":"Journal of clinical pharmacology"},{"key":"25","doi-asserted-by":"crossref","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"26","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","article-title":"Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells","volume":"188","author":"Perussia","year":"1998","journal-title":"The Journal of experimental medicine"},{"key":"27","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Sadelain","year":"2007","journal-title":"Clinical cancer research"},{"key":"28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/hum.2013.075","article-title":"Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia","volume":"24","author":"Zhao","year":"2013","journal-title":"Human gene therapy"},{"key":"29","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Brenner","year":"2015","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Buzyn","year":"2014","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Kochenderfer","year":"2013","journal-title":"Clinical cancer research"},{"key":"32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1749-6632.1993.tb38780.x","article-title":"Potential clinical applications of signal transduction measurements in marrow transplantation and HIV-1 infection","volume":"677","author":"Lum","year":"1993","journal-title":"Annals of the New York Academy of Sciences"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:14:29Z","timestamp":1718730869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":32,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,8,30]]}},"alternative-id":["11019","27494836"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11019","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]}}}